DMRA · DAMORA THERAPEUTICS INC

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Building 23, Waltham, MA, 02453, United States
Biotechnology
Healthcare

Market Cap

1.393B

52 Wk Range

$15.76 - $38.33

Previous Close

$22.50

Open

$22.53

Volume

395,988

Day Range

$21.89 - $22.75

Enterprise Value

939.8M

Cash

528.5M

Avg Qtr Burn

-17.23M

Insider Ownership

8.41%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026